TIGIT and cancer: The co-expression of these two markers on MDSCs is both frequent and mechanistically intertwined, but each employs unique mechanisms to limit the binding activity of CD226, providing a rational basis for the combined targeting of PD-(L)1 and TIGIT in cancer immunotherapy [61].